Department of Pharmacology and Toxicology, and Section of Endocrinology, Diabetes and Metabolism, University of the Philippines Manila College of Medicine, Manila, Metro Manila, Philippines.
Section of Endocrinology, Diabetes, Metabolism and Nutrition, Ospital ng Makati, Makati, Metro Manila, Philippines.
BMJ Open. 2021 Oct 11;11(10):e049737. doi: 10.1136/bmjopen-2021-049737.
To estimate the annual direct medical cost of type 2 diabetes mellitus (T2DM) in hospitals and outpatient care clinics from a healthcare payer perspective in the Philippines.
(1) A review of electronic hospital records of people with T2DM in two tertiary hospitals-Ospital ng Makati (OsMak) and National Kidney and Transplant Institute (NKTI) and (2) a cross-sectional survey with 50 physicians providing outpatient care for people with T2DM.
Primary, secondary and tertiary healthcare facilities in Metro Manila.
Cost of managing T2DM and its related complications in US dollars (USD) in 2016.
A total of 1023 and 1378 people were identified in OsMak and NKTI, with a complication rate of 66% and 74%, respectively. In both institutions, the average annual cost per person was higher if individuals were diagnosed with any complication (NKTI: US$3226 vs US$2242 and OsMak: US$621 vs US$127). Poor diabetes control was estimated to incur higher per person cost than good control in both public outpatient care (poor control, range: US$727 to US$2463 vs good control, range: US$614 to US$1520) and private outpatient care (poor control, range: US$848 to US$2507 vs good control, range: US$807 to US$1603).
The results highlight the high direct medical cost resulting from poor diabetes control and the opportunity for cost reduction by improving control and preventing its complications.
从医疗付费方角度估计菲律宾医院和门诊护理诊所 2 型糖尿病(T2DM)的年度直接医疗费用。
(1)对两家三级医院——马卡蒂医院(OsMak)和国家肾脏和移植研究所(NKTI)的 T2DM 患者的电子病历进行审查,以及(2)对 50 名为 T2DM 患者提供门诊护理的医生进行横断面调查。
马尼拉大都会的初级、二级和三级医疗设施。
2016 年以美元(USD)计的 T2DM 及其相关并发症管理成本。
在 OsMak 和 NKTI 中分别确定了 1023 人和 1378 人,并发症发生率分别为 66%和 74%。在这两个机构中,如果个人被诊断出患有任何并发症,那么每个人的平均年费用都更高(NKTI:US$3226 比 US$2242,OsMak:US$621 比 US$127)。在公共门诊护理中,较差的糖尿病控制估计比良好的控制会导致更高的人均成本(较差的控制,范围:US$727 至 US$2463 比良好的控制,范围:US$614 至 US$1520),而在私人门诊护理中,较差的控制也比良好的控制导致更高的人均成本(较差的控制,范围:US$848 至 US$2507 比良好的控制,范围:US$807 至 US$1603)。
这些结果突出了因糖尿病控制不佳而导致的直接医疗费用高昂,以及通过改善控制和预防并发症来降低成本的机会。